BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Apixaban
Drug: Dabigatran
Drug: Rivaroxaban

First Posted Date: 2016-04-28

Last Posted Date: 2022-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 321182

Registration Number: NCT02754154

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Advanced Cancer

Interventions: Biological: Nivolumab
Biological: Relatlimab
Biological: Ipilimumab
Drug: BMS-986205
Drug: Dasatinib

First Posted Date: 2016-04-25

Last Posted Date: 2021-03-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 295

Registration Number: NCT02750514

Locations: 🇺🇸
University of Southern California (USC), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Californa, Los Angeles (UCLA), Los Angeles, California, United States

and more 35 locations

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Phase 3

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Other: Placebo
Drug: Nivolumab

First Posted Date: 2016-04-19

Last Posted Date: 2023-09-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 794

Registration Number: NCT02743494

Locations: 🇵🇱
Local Institution - 0138, Krakow, Poland
🇺🇸
Local Institution - 0250, Tucson, Arizona, United States
🇺🇸
Local Institution - 0226, Miami, Florida, United States

and more 200 locations

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: Nivolumab
Drug: Cetuximab/Erbitux
Biological: Ipilimumab
Drug: Cisplatin/Platinol
Drug: Carboplatin/Paraplatin
Drug: Fluorouracil/Adrucil

First Posted Date: 2016-04-18

Last Posted Date: 2023-09-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 947

Registration Number: NCT02741570

Locations: 🇺🇸
Local Institution - 0111, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0006, Chicago, Illinois, United States
🇺🇸
Local Institution - 0013, Pittsburgh, Pennsylvania, United States

and more 129 locations

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Phase 1

Completed

Conditions: Severe Sepsis

Interventions: Other: Placebo
Drug: BMS-986189

First Posted Date: 2016-04-15

Last Posted Date: 2018-02-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT02739373

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Evansville, Indiana, United States

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

Completed

Conditions: Melanoma

Interventions: Biological: Ipilimumab

First Posted Date: 2016-04-15

Last Posted Date: 2017-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 370

Registration Number: NCT02739386

Locations: 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986178
Drug: Ipilimumab
Drug: Nivolumab
Biological: Tetanus vaccine
Biological: DPV-001 vaccine
Drug: Cyclophosphamide

First Posted Date: 2016-04-14

Last Posted Date: 2022-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 166

Registration Number: NCT02737475

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇮🇹
IRCCS Istituto Nazionale Tumori Milano, Milano, Italy
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 14 locations

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Completed

Conditions: Chronic Myeloid Leukemia (CML)

Interventions: Drug: dasatinib
Drug: nilotinib

First Posted Date: 2016-04-11

Last Posted Date: 2016-04-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2650

Registration Number: NCT02733445

Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea

Completed

Conditions: Hepatitis C

First Posted Date: 2016-04-05

Last Posted Date: 2022-01-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1941

Registration Number: NCT02727933

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Nivolumab
Biological: Elotuzumab
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2016-04-01

Last Posted Date: 2023-03-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 170

Registration Number: NCT02726581

Locations: 🇺🇸
Local Institution - 0035, Chicago, Illinois, United States
🇸🇪
Local Institution - 0064, Huddinge, Sweden
🇺🇸
Local Institution - 0016, Fountain Valley, California, United States

and more 108 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy